Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Aug;29(8):104941.
doi: 10.1016/j.jstrokecerebrovasdis.2020.104941. Epub 2020 May 12.

Coronavirus Disease 2019 and Stroke: Clinical Manifestations and Pathophysiological Insights

Affiliations
Review

Coronavirus Disease 2019 and Stroke: Clinical Manifestations and Pathophysiological Insights

Afshin A Divani et al. J Stroke Cerebrovasc Dis. 2020 Aug.

Abstract

Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a global health threat. Some COVID-19 patients have exhibited widespread neurological manifestations including stroke. Acute ischemic stroke, intracerebral hemorrhage, and cerebral venous sinus thrombosis have been reported in patients with COVID-19. COVID-19-associated coagulopathy is increasingly recognized as a result of acute infection and is likely caused by inflammation, including inflammatory cytokine storm. Recent studies suggest that axonal transport of SARS-CoV-2 to the brain can occur via the cribriform plate adjacent to the olfactory bulb that may lead to symptomatic anosmia. The internalization of SARS-CoV-2 is mediated by the binding of the spike glycoprotein of the virus to the angiotensin-converting enzyme 2 (ACE2) on cellular membranes. ACE2 is expressed in several tissues including lung alveolar cells, gastrointestinal tissue, and brain. The aim of this review is to provide insights into the clinical manifestations and pathophysiological mechanisms of stroke in COVID-19 patients. SARS-CoV-2 can down-regulate ACE2 and, in turn, overactivate the classical renin-angiotensin system (RAS) axis and decrease the activation of the alternative RAS pathway in the brain. The consequent imbalance in vasodilation, neuroinflammation, oxidative stress, and thrombotic response may contribute to the pathophysiology of stroke during SARS-CoV-2 infection.

Keywords: ACE2; COVID-19; Endothelial damage; Pandemic; Renin-angiotensin system; SARS-CoV-2; Stroke.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors declare no conflict of interest with regard to this paper.

Figures

Fig. 1:
Fig. 1
Schematic process of endocytosis of SARS-COV-2, proliferation of the virus inside the cell, and effect of virus upon RAS. Having been primed by TMPRSS2, SARS-COV-2’s spike glycoprotein binds to ACE2. The virus enters the cell and is proliferated. SARS-COV-2 downregulates ACE2, which in turn under-activates the RAS alternative axis (ACE2-Ang-(1-7)-Mas). Under-activation of the alternative axis gives rise to over-activation of the classical RAS axis (ACE-Ang II-AT1R). The consequent imbalance in vasodilation, neuroinflammation, oxidative stress, and thrombotic response can contribute to the pathophysiology of stroke during SARS-CoV-2 infection. Abbreviations: SARS-COV-2: severe acute respiratory syndrome coronavirus 2, RAS: renin-angiotensin system, ACE2: angiotensin-converting enzyme 2, TMPRSS2: Transmembrane protease, serine 2, Ang: angiotensin, Mas: Mas receptor, AT1R: angiotensin 1 receptor.
Fig. 2:
Fig. 2
Non-contrast head CT showing posterior fossa ICH with acute obstructive hydrocephalus in a COVID-19 positive patient.

Similar articles

Cited by

References

    1. Zhou P., Yang X.-L., Wang X.-G. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270–273. doi: 10.1038/s41586-020-2012-7. - DOI - PMC - PubMed
    1. Wu A., Peng Y., Huang B. Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host Microbe. 2020;27:325–328. doi: 10.1016/j.chom.2020.02.001. - DOI - PMC - PubMed
    1. He F., Deng Y., Li W. Coronavirus disease 2019: What we know? J Med Virol. 2020 doi: 10.1002/jmv.25766. [ahead of print] - DOI - PMC - PubMed
    1. Wang Y., Wang Y., Chen Y. Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures. J Med Virol. 2020;92:568–576. doi: 10.1002/jmv.25748. - DOI - PMC - PubMed
    1. WHO. Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003. https://www.who.int/csr/sars/country/table2004_04_21/en/. Published Dec 31, 2003. Accessed April 28, 2020.

MeSH terms

Substances